PD0325901

Licensed by Pfizer 製品コードS1036

PD0325901化学構造

分子量(MW):482.19

PD0325901 is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM in cell-free assays, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 2.

サイズ 価格(税別)  
JPY 23240.00
JPY 11620.00
JPY 44820.00
JPY 127820.00

文献中Selleckの製品使用例(76)

カスタマーフィードバック(19)

  • Phosphorylation of PPARg in epididymal white adipose tissue in ob/ob mice after treatment with MEK inhibitors. Gene expression in ob/ob epididymal white adipose tissue after treatment with vehicle or either of two MEK inhibitors, PD0325901 or GSK1120212 (n = 7, 7 and 8, respectively). Areas under the curve and gene expression were analysed by analysis of variance.

    Nature 2015 517(7534), 391-5. PD0325901 purchased from Selleck.

    Immunoblot analysis of Ser9-phosphorylated (that is, inactivated) or total GSK3β, active or total β-catenin Thr202- and Tyr204- phosphorylated or total Erk1/2, and Ser473-phosphorylated or total Akt in control; Bcl2 lymphoma cells treated with ADR for five days, together with pharmacological inhibitors targeting MAPK and PI3K kinase pathways.α -Tubulin was used as a loading control. MAPKi=PD325901.

    Nature, 2018, 553(7686):96-100. PD0325901 purchased from Selleck.

  • c, Examples of CDK2 activity traces aligned to the end of mitosis. Each panel shows different time windows relative to mitosis when mitogens were withdrawn (marked in grey) in d. d, Probability of proliferation (defined as CDK2 activity > 1, 10 h after mitosis) represented as a function of time when inhibitors of MEK (MEKi; 100 nM PD0325901) or of CDK4 (CDK4i; 1 μ M palbociclib) were added or when mitogens were removed, relative to mitosis. Data are mean ± s.e.m. (n = 5 biological replicates).

    Nature, 2017, 549(7672):404-408. PD0325901 purchased from Selleck.

    Immunoblot analysis of Ser9-phosphorylated (that is, inactivated) or total GSK3β , active or total β -catenin (as in Extended Data Fig. 5c), Thr202- and Tyr204-phosphorylated or total Erk1/2, and Ser473-phosphorylated or total Akt in control;Bcl2 lymphoma cells treated with ADR for five days, together with pharmacological inhibitors targeting MAPK and PI3K kinase pathways. α -Tubulin was used as a loading control. One out of two independent experiments shown. MPAKi:PD325901

    Nature, 2017, 553(7686):96-100. PD0325901 purchased from Selleck.

  • Rapamycin reduces VCAM expression in vivo. Expression of VCAM-1 mRNA (normalized to CD31) in aortas harvested from mice pretreated with vehicle, rapamycin, or rapamycin + MEK inhibitor (MEK-I; PD0325901) and then injected with TNF (n = 5 per group). Mice were treated as in D. Harvested aortas were analyzed for VCAM-1 expression via immunofluorescence.

    J Exp Med 2014 211(3), 395-404. PD0325901 purchased from Selleck.

    Plasma MEK inhibitor levels of PD325901 are plotted against % MEK inhibition in brain. One hundred percent pERK levels (0% MEK inhibition) were determined in vehicle-treated rats.Inhibition of pERK activity in brain, lung, and Colo205 tumor in nude xenograft mice treated with 10 mg/kg PD325901.

     

     

    Cancer Res 2009 PD0325901 purchased from Selleck.

  • Pharmacological inhibition of MEK (PD0325901) suppresses DR5 expression in cancer cells; this effect is reversible upon stopping of the treatment. The indicated cancer cell lines were exposed to the given concentrations of the inhibitors as indicated for 16 h. TPC-1 cells were treated with 10 uM of the indicated inhibitors for different times as labeled.

    Oncogene 2015 10.1038/onc.2015.97. PD0325901 purchased from Selleck.

    (B)Effect of MAPK pathway inhibition on FGF9 mediated induction of Fgf23 expression. (D) Western blot analysis of FRS2 and ERK1/2 phosphorylation in UMR 106 cells. Cells were treated for 3h (Western blot) or 24h (qPCR analysis) with FGF9 (50ng/ml), EGF (50ng/ml), PD173074 (250nM), PD0325901 (100nM) and RAF265 (500nM) as indicated. Heparin (10g/ml) was added to all treatments with FGF9. Activation of Fgf23 is shown relative to transcript levels in vehicle treated cells (relative expression of 1). Expression values were normalized to Gapdh mRNA copies and are given as average with SEM (n3). Data were compared by 1 way ANOVA; asterisk indicates p<0.05 with respect to vehicle treated cells.

    J Bone Miner Res 2011 26, 2486-2497. PD0325901 purchased from Selleck.

  • Assessment of in vivo toxicity to MEK inhibitor PD0325901. (A) Weight change in grams is shown for each PD0325901 (PD) treatment group in the MDA-MB-453 xenograft model. Weight change is the difference between pre- and post-treatment weight in each group. PD0325901 treatments were carried out at 5, 10, 15 and 20 mg/kg/day for 30 days, and daily gavage of carrier solution was used as control. *P < 0.01 for PD-5/PD-10 vs. control groups and PD-5/PD-10 vs. PD-15/PD-20 groups using Mann-Whitney U test. Error bars: ±2 SEM. (B) Number of days lost due to toxicity is shown for each PD0325901 treatment group in mouse xenograft model explained in Figure 5A. *P < 0.01 for PD-5/PD-10 vs. PD-15/PD-20 groups.

     

     

    Breast Cancer Res 2011 13, R36. PD0325901 purchased from Selleck.

    The therapeutic effect of AR and MEK inhibitors on in vivo angiogenesis. (A) Angiogenesis index for each in vivo treatment group. Angiogenesis was measured as the number of CD-31-positive blood vessels in a cross-section of each xenograft tumor. CTL: control group; FLU: flutamide; and PD: PD0325901. *P < 0.03 for PD0325901 monotherapy vs. control and **P < 0.03 for combination therapy vs. monotherapy groups using Mann-Whitney U test. Error bars: ±2 SEM. (B) Immunohistochemistry (IHC) was used to measure angiogenesis in a control xenograft tumor. Staining was performed using a CD31 rabbit polyclonal antibody. Original magnification, × 40. (C) IHC was used to measure angiogenesis in a PD0325901 monotherapy tumor. Original magnification, × 40. (D) IHC was used to measure angiogenesis in a xenograft tumor treated with combination therapy. Original magnification, × 40.

    Breast Cancer Res 2011 13, R36. PD0325901 purchased from Selleck.

  • Effects of the MEK inhibitor (MEKi) PD0325901 (PD) and rhBMP-2 (BMP) treatment on histology in an NF1 open fracture model. Treatment with 10 mg/kg of PD0325901 on days 22 through 10 (PD alone) slightly improved bone volume and callus size. Delivery of 10 mg of rhBMP-2 in the collagen sponge (BMP alone) resulted in a large increase in bone volume and callus size. Combination treatment with local rhBMP-2 and systemic PD0325901 (PD 1 BMP) resulted in further increases in new bone volume and total callus volume.Picro Sirius Red and Alcian Blue staining to assess fibrous tissue.

    J Bone Joint Surg Am 2015 96(14), e117. PD0325901 purchased from Selleck.

    Bone 2014 59, 151-61. PD0325901 purchased from Selleck.

  •  

    Characterization of rES cells. A: image of normal rES cell colonies on feeder layers. B: rES colonies were positive for AP staining. CeE: rES colonies readily expressed pluripotent markers, Sox2 (C), Oct4 (D), and SSEA-1 (E). Blue, DAPI. Scale bars: 100 um.

    J Genet Genomics 2012 39, 643e651. PD0325901 purchased from Selleck.

     

    Effect of small molecule inhibitors on reprogramming efficiency of myoblast cell derived from 5 different donors. (A) Reprogramming efficiency is shown as number of colonies from 10^5 starting cells on Y-axes. Ctrl, control condition and addition of small molecule inhibitors are marked. (B) AP staining of reprogrammed myoblast cell lines,from 5 different donors, in wells of 12-well plates at day 18. Ctrl, control condition and additions of small molecule inhibitors are marked.

    Stem Cells Dev 2013 PD0325901 purchased from Selleck.

  • The effects of PD0325901 on the Akt/mTOR and MAPK pathways in the two DDLS cell lines as evaluated by western blotting

    Tumour Biol, 2016, 37(4):4767-76.. PD0325901 purchased from Selleck.

    PD0325901 inhibited the sorafenib-induced RAS/ERK pathway activation and enhanced the cytotoxic effects of sorafenib in resistant cell lines. (A) HUH-7 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (PD0325901, 10 μM). Expressions of p-AKT and cleaved PARP were revealed by Western blotting. (B) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (PD0325901, 10 μM). Expressions of p-AKT and cleaved PARP were revealed by Western blotting. (C) HUH-7 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. Proportions of apoptotic cells were evaluated by annexin V labeling. (D) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. Proportions of apoptotic cells were evaluated by annexin V labeling. (*P<0.05, HUH- 7, SK-HEP-1 are control groups, R-HUH-7, R-SK-HEP-1 are resistant groups).

    J Surg Res, 2016, 206(2):371-379. PD0325901 purchased from Selleck.

  • Inhibition of anchorage-independent growth of lung tumor cell lines by selected inhibitors. Each selected cell line was treated with the indicated inhibitor at 0.1 μM and 1 μM concentrations for two weeks and cell colony size formation was scored under the Nikon inverted-phase microscope.

    Int J Proteomics 2011 2011, Article ID 215496. PD0325901 purchased from Selleck.

    Breast cancer cells were pretreated with 100ng/ml EGF for 15 min and then treated with the indicated concentrations of  PD0325901 for 24 hours.

     

     

    2010 Dr Zhang of Tianjin Medical University. PD0325901 purchased from Selleck.

  • Effects of PD0325901 on HT29 Xenograft tumors. PD0325901(1mg/kg carrier DMSO).Collection at 24h.

     

     

    2010 Dr. Citrin, Deborah of NIH. PD0325901 purchased from Selleck.

製品安全説明書

MEK阻害剤の選択性比較

生物活性

製品説明 PD0325901 is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM in cell-free assays, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 2.
ターゲット
MEK [1]
(Cell-free assay)
0.33 nM
体外試験

PD0325901 shows higher permeability than CI-1040, another MEK inhibitor. PD0325901 should be able to achieve higher systemic exposures than CI-1040. [1] PD0325901 is exquisitely specific and highly potent against purified MEK, revealing a Kiapp of 1 nM against activated MEK1 and MEK2. [2] PD0325901 is roughly 500-fold more potent than CI-1040 with respect to its cellular effects on phosphorylation of ERK1 and ERK2, displaying subnanomolar activity. [2] PD0325901 prevents the growth of melanoma cell lines. PD0325901 inhibits the growth of TPC-1 cells and K2 cells with GI50 of 11 nM and 6.3 nM, respectively. [3] PD0325901 significantly prevents the the growth of PTC cells harboring a BRAF mutation at very low concentration (10 nM) and only moderately increases the growth of the PTC cells carrying the RET/PTC1 rearrangement at the same concentration. PD0325901 effectively inhibits the phosphorylation of ERK1/2 in multiple PTC cell lines. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human CHP-212 cell NWHv[FllT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M17iSmlvcGmkaYTpc44hd2ZiaIXtZY4hS0iSLUKxNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPTJ5IH7NMi=> M1HW[nNCVkeHUh?=
human M14 cell NI\IdlNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVjJcohq[mm2aX;uJI9nKGi3bXHuJG0yPCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwNEWgcm0v MnfaV2FPT0WU
human SK-MEL-28 cell MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGLOR5FKdmirYnn0bY9vKG:oIHj1cYFvKFONLV3FUE0zQCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwNUKgcm0v NVTFSJZ[W0GQR1XS
human NOMO-1 cell M2XMU2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnvTTY5pcWKrdHnvckBw\iCqdX3hckBPV02RLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlA4KG6PLh?= MVnTRW5ITVJ?
human A375 cell MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWTJcohq[mm2aX;uJI9nKGi3bXHuJGE{PzViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{Lk[5JI5ONg>? M2rreHNCVkeHUh?=
human DU-4475 cell MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGHid3FKdmirYnn0bY9vKG:oIHj1cYFvKESXLUS0O|Uh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjV5IH7NMi=> MYXTRW5ITVJ?
human C32 cell M3HGdGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXHJcohq[mm2aX;uJI9nKGi3bXHuJGM{OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTNwNkegcm0v MlTyV2FPT0WU
human BPH-1 cell MoTzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mlq3TY5pcWKrdHnvckBw\iCqdX3hckBDWEhvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuPVUhdk1w NVf3SIpLW0GQR1XS
human CP50-MEL-B cell M{\uUmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkLITY5pcWKrdHnvckBw\iCqdX3hckBEWDVyLV3FUE1DKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC53ODDuUU4> MULTRW5ITVJ?
human H9 cell M2HrOmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnTETY5pcWKrdHnvckBw\iCqdX3hckBJQSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwN{egcm0v NUDsTVlQW0GQR1XS
human HTC-C3 cell MojHS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkTITY5pcWKrdHnvckBw\iCqdX3hckBJXENvQ{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlg6KG6PLh?= M{T3enNCVkeHUh?=
human BHT-101 cell NILDUlJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYPJcohq[mm2aX;uJI9nKGi3bXHuJGJJXC1zMEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22Mlchdk1w MWPTRW5ITVJ?
human COLO-741 cell NFnFTGRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHnuWmZKdmirYnn0bY9vKG:oIHj1cYFvKEORTF:tO|QyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py5zIH7NMi=> NVftRm1KW0GQR1XS
human OVCAR-5 cell Mm\zS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MofxTY5pcWKrdHnvckBw\iCqdX3hckBQXkODUj21JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{45OiCwTT6= NEf4UJRUSU6JRWK=
human A549 cell MkPkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIX6WHdKdmirYnn0bY9vKG:oIHj1cYFvKEF3NEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23Mlg6KG6PLh?= M175UHNCVkeHUh?=
human SH-4 cell growth M3vuNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGHaZVFKdmirYnn0bY9vKG:oIHj1cYFvKFOKLUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24MlI3KG6PLh?= MUXTRW5ITVJ?
human SK-N-AS cell MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVjJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU5vQWOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24MlQ1KG6PLh?= MnT4V2FPT0WU
human HT-144 cell MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MX;Jcohq[mm2aX;uJI9nKGi3bXHuJGhVNTF2NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUiuPVchdk1w NXu0T|BUW0GQR1XS
human MEL-HO cell MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3nsW2lvcGmkaYTpc44hd2ZiaIXtZY4hVUWOLVjPJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PU41QSCwTT6= MYTTRW5ITVJ?
human COLO-679 cell NGTVeIFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEDzeG1KdmirYnn0bY9vKG:oIHj1cYFvKEORTF:tOlc6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTBwMEGgcm0> MUDTRW5ITVJ?
human HuP-T4 cell NGq4WWRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NF;0O|lKdmirYnn0bY9vKG:oIHj1cYFvKEi3UD3UOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVExNjl6IH7NMi=> NVLBOpE2W0GQR1XS
human H-EMC-SS cell MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUPpXppPUW6qaXLpeIlwdiCxZjDoeY1idiCKLVXNR{1UWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFzLkCyJI5ONg>? MYDTRW5ITVJ?
human LB2518-MEL cell MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1HvOGlvcGmkaYTpc44hd2ZiaIXtZY4hVEJ{NUG4MW1GVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFzLkGzJI5ONg>? M3rSenNCVkeHUh?=
human HL-60 cell MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4jheWlvcGmkaYTpc44hd2ZiaIXtZY4hUExvNkCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNU4yPSCwTT6= M4jkSXNCVkeHUh?=
human NCI-H1666 cell NH3SbJBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4XXXGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOlY3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTFwMUegcm0v M2DuWnNCVkeHUh?=
human A101D cell NVTHUZl7T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUTVd3BqUW6qaXLpeIlwdiCxZjDoeY1idiCDMUCxSEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEyNjR3IH7NMi=> MnrRV2FPT0WU
human RVH-421 cell NGnWTVdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUPJcohq[mm2aX;uJI9nKGi3bXHuJHJXUC12MkGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNk43PCCwTT6= NIfHXVdUSU6JRWK=
human Hs-578-T cell M3LlWmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{LmbWlvcGmkaYTpc44hd2ZiaIXtZY4hUHNvNUe4MXQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yOi55OTDuUU4> NFL2UpRUSU6JRWK=
human A375 cells MUfQdo9tcW[ncnH0bY9vKGG|c3H5 NUHmcXVKPzJiaB?= MUTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF|N{WgZ4VtdHNiZYjwdoV{e2mwZzDCVmFHKFZ4MEDFJI12fGGwdDDh[pRmeiB5MjDodpMh[nliQ3XscEB1cXSncj3ncI8h[XO|YYmsJGlEPTB;MUOgcm0v NEXMVY8zOzR5NEO4PC=>
human DOK cell NUi2bJltT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1;5cGlvcGmkaYTpc44hd2ZiaIXtZY4hTE:NIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUOuOEBvVS5? NH7LNppUSU6JRWK=
human Mewo cell M4CzWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlTDTY5pcWKrdHnvckBw\iCqdX3hckBO\XexIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUSuOFUhdk1w Mkf5V2FPT0WU
human ONS-76 cell M2DBUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NI\mWFFKdmirYnn0bY9vKG:oIHj1cYFvKE:QUz23OkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE1NjVzIH7NMi=> NEP4bZpUSU6JRWK=
human UACC-257 cell M3f0XWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYnJcohq[mm2aX;uJI9nKGi3bXHuJHVCS0NvMkW3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVQvPjJibl2u MUHTRW5ITVJ?
human SW626 cell NFrxT2NIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUTyNYJyUW6qaXLpeIlwdiCxZjDoeY1idiCVV{[yOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE1NjlzIH7NMi=> NYXhfIpKW0GQR1XS
human SW620 cell NHXteXNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4fBcmlvcGmkaYTpc44hd2ZiaIXtZY4hW1d4MkCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOE46PSCwTT6= NHv2OZBUSU6JRWK=
human TYK-nu cell MnP3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mn7hTY5pcWKrdHnvckBw\iCqdX3hckBVYUtvboWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOU4yOyCwTT6= NVjGd5puW0GQR1XS
human ACN cell M1H1dWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NX7SWnhGUW6qaXLpeIlwdiCxZjDoeY1idiCDQ16gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOU44PiCwTT6= NXvqV4hlW0GQR1XS
human MIAPaCa2 cells NXzpVnB5WHKxbHnm[ZJifGmxbjDhd5NigQ>? MUfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2LQWDhR4EzKGOnbHzzMEBKSzVyPUG3JI5ONg>? M1PiRVI{PDd2M{i4
human T-24 cell NU\VN|FoT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MX;Jcohq[mm2aX;uJI9nKGi3bXHuJHQuOjRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zOT63NUBvVS5? M1zETXNCVkeHUh?=
human AGS cell Mn7hS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXzJcohq[mm2aX;uJI9nKGi3bXHuJGFIWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJyLkSxJI5ONg>? NGnSSo1USU6JRWK=
human SW872 cell NUi0TIlRT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFHCZ3NKdmirYnn0bY9vKG:oIHj1cYFvKFOZOEeyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlcvQTlibl2u MYHTRW5ITVJ?
human C2BBe1 cell MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHWwWllKdmirYnn0bY9vKG:oIHj1cYFvKEN{QlLlNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVI5NjV2IH7NMi=> NVi4fVU{W0GQR1XS
human MZ7-mel cell NIHhV|JIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1HuS2lvcGmkaYTpc44hd2ZiaIXtZY4hVVp5LX3lcEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVI6NjR|IH7NMi=> M1XPU3NCVkeHUh?=
human HCC2998 cell NILWUVZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWnJcohq[mm2aX;uJI9nKGi3bXHuJGhESzJ7OUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zN{43PiCwTT6= MnjjV2FPT0WU
human HO-1-N-1 cell MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mn\QTY5pcWKrdHnvckBw\iCqdX3hckBJVy1zLV6tNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVM1NjR|IH7NMi=> M1Hh[HNCVkeHUh?=
human SW756 cell MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEnZfHFKdmirYnn0bY9vKG:oIHj1cYFvKFOZN{W2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N|QvPDVibl2u MnLoV2FPT0WU
human NCI-H1437 cell M4n4fWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1PGNmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOFM4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OzRwNEmgcm0v M2fFR3NCVkeHUh?=
human NCI-H747 cell M3zufmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGrxRolKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IO|Q4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OzRwOUigcm0v NXvQPWJqW0GQR1XS
human SK-MEL-2 cell NIfFe3RIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NV7O[YpZUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3NSWwuOiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTN3LkKgcm0v MoT6V2FPT0WU
human MZ2-MEL cell M{Dibmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{THO2lvcGmkaYTpc44hd2ZiaIXtZY4hVVp{LV3FUEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVM2NjZ3IH7NMi=> NXzGUXpFW0GQR1XS
human PSN1 cell MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWLIW3pOUW6qaXLpeIlwdiCxZjDoeY1idiCSU16xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N|gvPDVibl2= NUWwRldZW0GQR1XS
human CAL-39 cell MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHjZZ|FKdmirYnn0bY9vKG:oIHj1cYFvKEODTD2zPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVM6NjB2IH7NMi=> NY[4fmd4W0GQR1XS
human LOXIMVI cell M3vON2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1yyWmlvcGmkaYTpc44hd2ZiaIXtZY4hVE:[SV3WTUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVM6NjN7IH7NMi=> MlTYV2FPT0WU
human COLO-792 cell NIjSNWRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVTaT2FIUW6qaXLpeIlwdiCxZjDoeY1idiCFT1zPMVc6OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTR|LkG1JI5ONg>? M360NHNCVkeHUh?=
human CAL-27 cell NXX4dWdxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUjJcohq[mm2aX;uJI9nKGi3bXHuJGNCVC1{NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUS0MlkyKG6P Ml;yV2FPT0WU
human AsPC-1 cell M{Llfmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXzJcohq[mm2aX;uJI9nKGi3bXHuJGF{WENvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUS1MlI5KG6PLh?= NYfkWW5{W0GQR1XS
human NCI-H2291 cell NWjrbo52T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVm5d|hFUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFIzQTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12Nj60OkBvVS5? MYXTRW5ITVJ?
human RCM-1 cell MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1XLNWlvcGmkaYTpc44hd2ZiaIXtZY4hWkOPLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Ok45PSCwTT6= M3TPUnNCVkeHUh?=
human NCI-H292 cell NX\oc2hsT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVX2[21lUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFI6OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTR5LkO5JI5ONg>? NWXseVdiW0GQR1XS
human WM-115 cell MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NF7ISHBKdmirYnn0bY9vKG:oIHj1cYFvKFePLUGxOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQ5NjVibl2u MoHEV2FPT0WU
human RT-112 cell MnHqS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFPhbVBKdmirYnn0bY9vKG:oIHj1cYFvKFKWLUGxNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQ5Njh2IH7NMi=> M2PZbXNCVkeHUh?=
human HT-29 cell NWLoO|JzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NInsW|VKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUK5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OVAvPDlibl2u NWHTUo1CW0GQR1XS
human RKO cell growth NIXJRZJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3\NeGlvcGmkaYTpc44hd2ZiaIXtZY4hWkuRIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NUKuNFIhdk1w NHjFPW5USU6JRWK=
human KY821 cell MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlX2TY5pcWKrdHnvckBw\iCqdX3hckBMYTh{MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWzMlMhdk1w M4DpfXNCVkeHUh?=
human LB1047-RCC cell M1LvS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MX\Jcohq[mm2aX;uJI9nKGi3bXHuJGxDOTB2Nz3SR2Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02QS54NTDuUU4> NYHyWphxW0GQR1XS
human SW1116 cell M2\ITGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWPJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTFzNjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[wMlQ6KG6PLh?= M4rLcXNCVkeHUh?=
human P12-ICHIKAWA cell NH\NWohIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXW1ZlR1UW6qaXLpeIlwdiCxZjDoeY1idiCSMUKtTWNJUUuDV1GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22Nk4zPyCwTT6= NVr1VmlXW0GQR1XS
human HCC70 cell M4fOeGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHH6e|lKdmirYnn0bY9vKG:oIHj1cYFvKEiFQ{ewJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OlMvODFibl2u Ml;RV2FPT0WU
human MIA-PaCa-2 cell MlvVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MorhTY5pcWKrdHnvckBw\iCqdX3hckBOUUFvUHHDZU0zKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PjNwNUOgcm0v NH7PSHVUSU6JRWK=
human LoVo cell M1foU2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4riUmlvcGmkaYTpc44hd2ZiaIXtZY4hVG:YbzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[1MlI6KG6PLh?= M1XtNnNCVkeHUh?=
human LB2241-RCC cell MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVTmcJNPUW6qaXLpeIlwdiCxZjDoeY1idiCOQkKyOFEuWkOFIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NkWuOVIhdk1w NGPIWVVUSU6JRWK=
human GAK cell MoL5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NV;TNZI1UW6qaXLpeIlwdiCxZjDoeY1idiCJQVugZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22Ok45PyCwTT6= NX7ZdY9xW0GQR1XS
human RD cell NFXNNHlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYjJcohq[mm2aX;uJI9nKGi3bXHuJHJFKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PjdwMTDuUU4> NVvIW3U5W0GQR1XS
human KNS-62 cell NGCyd5RIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mkm5TY5pcWKrdHnvckBw\iCqdX3hckBMVlNvNkKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22PU46QSCwTT6= M4nrVXNCVkeHUh?=
human HD-MY-Z cell MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUnJcohq[mm2aX;uJI9nKGi3bXHuJGhFNU2\LWqgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23NU4yOiCwTT6= MVnTRW5ITVJ?
human COR-L105 cell MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MX7Jcohq[mm2aX;uJI9nKGi3bXHuJGNQWi2OMUC1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O|EvPzFibl2u Mlf4V2FPT0WU
human IA-LM cell NHjoVoxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MV;Jcohq[mm2aX;uJI9nKGi3bXHuJGlCNUyPIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;N{OuNlghdk1w M17xNHNCVkeHUh?=
human EM-2 cell M2nkV2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2n3bWlvcGmkaYTpc44hd2ZiaIXtZY4hTU1vMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUe0Mlchdk1w NVzB[WFMW0GQR1XS
human NB69 cell MnnyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MX3Jcohq[mm2aX;uJI9nKGi3bXHuJG5DPjliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeR?= NHfoTYNUSU6JRWK=
human HuP-T3 cell M2DtV2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M37NZmlvcGmkaYTpc44hd2ZiaIXtZY4hUHWSLWSzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PFMvQTNibl2u MmLMV2FPT0WU
human BB30-HNC cell NGjPfItIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWjJcohq[mm2aX;uJI9nKGi3bXHuJGJDOzBvSF7DJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PFUvPTFibl2u NV7HUWo3W0GQR1XS
human HT-1080 cell NXe3fFEzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYnwco9kUW6qaXLpeIlwdiCxZjDoeY1idiCKVD2xNFgxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:QDVwOEigcm0v MXfTRW5ITVJ?
human RMG-I cell M4jMOWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1WzW2lvcGmkaYTpc44hd2ZiaIXtZY4hWk2JLVmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24O{4{PCCwTT6= NILwOZlUSU6JRWK=
human HCC1419 cell NV;5[YNVT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NW\HR2w2UW6qaXLpeIlwdiCxZjDoeY1idiCKQ1OxOFE6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:QTFwM{igcm0v MnrPV2FPT0WU
human SW780 cell MoHxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4q5PGlvcGmkaYTpc44hd2ZiaIXtZY4hW1d5OECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME25Nk4{OiCwTT6= MWfTRW5ITVJ?
human SNU-387 cell M2\H[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEHJU41KdmirYnn0bY9vKG:oIHj1cYFvKFOQVT2zPFch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF06Oy5|NjDuUS=> MUTTRW5ITVJ?
human LAMA-84 cell NUPOeIpYT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHnLTotKdmirYnn0bY9vKG:oIHj1cYFvKEyDTVGtPFQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF06PC54ODDuUU4> M4HWZnNCVkeHUh?=
human MV-4-11 cell NUHsO3hLT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MV7Jcohq[mm2aX;uJI9nKGi3bXHuJG1XNTRvMUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME25OE44OyCwTT6= NI\t[ZdUSU6JRWK=
human EGI-1 cell NYjiV4lkT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NH3WVWVKdmirYnn0bY9vKG:oIHj1cYFvKEWJST2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PVUvQDFibl2u Mn:4V2FPT0WU
human NCI-SNU-1 cell NWjhb4ZZT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGHUT4xKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3TUnUuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTl4LkezJI5ONg>? MlrXV2FPT0WU
human MEG-01 cell NFzGOHdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnmyTY5pcWKrdHnvckBw\iCqdX3hckBOTUdvMEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME25O{44PyCwTT6= M{TzOnNCVkeHUh?=
human OMC-1 cell NWXGOm5{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1qxWmlvcGmkaYTpc44hd2ZiaIXtZY4hV02FLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNFAvOjNibl2u NXrLeZN{W0GQR1XS
human NB10 cell NEnWe5lIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NH\rbmVKdmirYnn0bY9vKG:oIHj1cYFvKE6EMUCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNFAvPDJibl2u MlvOV2FPT0WU
human CAL-62 cell NGL5fGlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmjmTY5pcWKrdHnvckBw\iCqdX3hckBESUxvNkKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNFAvPzhibl2u MnyxV2FPT0WU
human NCI-H2087 cell MlvjS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHP1T4pKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlA5PyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFyMT6xOEBvVS5? NX23eIs2W0GQR1XS
human MDA-MB-175-VII cell MYrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnnLTY5pcWKrdHnvckBw\iCqdX3hckBOTEFvTVKtNVc2NV[LSTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5 NV3GRmx[W0GQR1XS
human LS-513 cell NYThO3VFT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mk\RTY5pcWKrdHnvckBw\iCqdX3hckBNWy13MUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNVQvQDNibl2u MWrTRW5ITVJ?
human HN cell growth MljuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mmq3TY5pcWKrdHnvckBw\iCqdX3hckBJViClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTF{Mj61PUBvVS5? MX7TRW5ITVJ?
human ABC-1 cell NXPTR3NKT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYLJcohq[mm2aX;uJI9nKGi3bXHuJGFDSy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUKzMlAzKG6PLh?= MlrMV2FPT0WU
human SJSA-1 cell MlfaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGfQSpdKdmirYnn0bY9vKG:oIHj1cYFvKFOMU1GtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEzOy5zOTDuUU4> NFjZfmRUSU6JRWK=
human PANC1 cells NEXIU|lHfW6ldHnvckBie3OjeR?= NV3DRWhxOTBizszN NHzCPZAyKGh? NXnqSFBwUW6qaXLpeIlwdiCxZjDNSWsyKGmwIHj1cYFvKFCDTlOxJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCyRYLrNU8zKGyndnXsJIF1KDFyIIXNJIFnfGW{IEGgbJIh[nliV3XzeIVzdiCkbH;0eIlv\yCjbnHsfZNqew>? MXeyOVc3PjZ|Mx?=
human MCF7 cells MnHiSpVv[3Srb36gZZN{[Xl? M{H0eFc2KG2rboO= MVvJcohq[mm2aX;uJI9nKE2Ha{GvNkBqdiCqdX3hckBOS0Z5IHPlcIx{KGG|c3Xzd4VlKGG|IHTlZ5Jm[XOnIHnuJGVTUyCyaH;zdIhwenmuYYTpc44h[W[2ZYKgO|UhdWmwczDifUBY\XO2ZYLuJIJtd3S2aX7nJIFv[Wy7c3nz MYCyN|M6QDR3Mx?=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 The improved potency of PD0325901 relative to CI-1040 is evident. A single oral dose of PD0325901 (25 mg/kg) inhibits phosphorylation of ERK by more than 50% at 24 hours post-dosing. In contrast, CI-1040 at a much higher dose (150 mg/kg) only inhibit pERK levels for roughly 8 hours, returning to control levels by 24 hours after treatment. [2] Therefore, the dose required to produce a 70% incidence of complete tumor responses (C26 model) is 25 mg/kg/day versus 900 mg/kg/day for PD0325901 and CI-1040, respectively. Anticancer activity of PD 0325901 has been demonstrated for a broad spectrum of human tumor xenografts. [2] After 1 week of oral administration of PD0325901 (20–25 mg/kg/day) in mice, no tumor growth is detected in mice inoculated with PTC cells bearing a BRAF mutation. [3] For PTC with the RET/PTC1 rearrangement, the average tumor volume of the orthotopic tumor is decreased by 58% as compared with controls. In conclusion, PTC cells carrying a BRAF mutation are more sensitive to PD0325901 than are PTC cells carrying the RET/PTC1 rearrangement. [3]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

In vitro cascade assay:

Incorporation of 32P into myelin basic protein (MBP) is assayed in the presence of a glutathione S-transferase fusion protein containing p44MAP kinase (GST-MAPK) and a glutathione S-transferase protein containing p45MEK (GST-MEK). The assay solution contained 20 mM HEPES, pH 7.4, 10 mM MgCl2, 1 mM MnCl2, 1 mM EGTA, 50 mM [gamma-32P]ATP, 10 mg GST-MEK, 0.5 mg GST-MAPK and 40 mg MBP in a final volume of 100 mL. Reactions are stopped after 20 minutes by addition of trichloroacetic acid and filtered through a GF/C filter mat. 32P retained on the filter mat is determined using a 1205 Betaplate. PD0325901 is assessed at various dose ranges in order to determine dose response curves.
細胞試験:

[3]

+ 展開
  • 細胞株: PTC cells
  • 濃度: 0.1 nM- 1 μM
  • 反応時間: 48 hours
  • 実験の流れ:

    PTC cells (1 × 104) are seeded in 24-well plates with 1 mL of medium for 4 days in a 37 °C incubator. MEK inhibitor PD0325901 at varying concentrations is added to the cells in triplicate on day 0. MTT dissolved in 0.8% NaCl solution at 5 mg/mL is added to each well (0.2 mL) on day 2 to test GI50 or every day for cell growth curves. The cells are incubated at 37 °C for 3 hours with MTT. The liquid is then aspirated from the wells and discarded. Stained cells are dissolved in 0.5 mL of DMSO and their absorption at 570 nm is measured using a Synergy HT multidetection microplate reader. For GI50, cell growth is calculated as 100 × (T − T0)/(C − T0), where T is the optical density of the wells treated with inhibitors after a 48-hour period, T0 is the optical density at time zero, and C is the control optical density with DMSO only.


    (参考用のみ)
動物試験:

[3]

+ 展開
  • 動物モデル: Ncr-nu/nu mice bearing PTC cells
  • 製剤: 80 mM citric buffer (pH 7)
  • 投薬量: 20-25 mg/kg
  • 投与方法: Oral gavage
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 96 mg/mL (199.09 mM)
Ethanol 40 mg/mL (82.95 mM)
Water Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
30% PEG 400+5% Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
10mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 482.19
化学式

C16H14F3IN2O4

CAS No. 391210-10-9
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02510001 Recruiting Solid Tumor|Colorectal Cancer University of Oxford|Queen''s University Belfast|Oxford University Hospitals NHS Trust|Velindre NHS Trust|University Hospital Antwerp|Hospital Vall d''Hebron|Saint Antoine University Hospital|European Georges Pompidou Hospital|Pfizer|University of Turin Italy|Belfast Health and Social Care Trust|Beaumont Hospital|European Commission|Array BioPharma|University of Paris 5 - Rene Descartes November 2014 Phase 1
NCT02096471 Active not recruiting Neurofibromatosis Type 1 and Growing or Symptomatic Inoperable PN University of Alabama at Birmingham June 2014 Phase 2
NCT02039336 Recruiting Colorectal Cancer The Netherlands Cancer Institute|Pfizer January 2014 Phase 1|Phase 2
NCT02022982 Active not recruiting KRAS Mutant Non-Small Cell Lung Cancer|Solid Tumors Dana-Farber Cancer Institute January 2014 Phase 1|Phase 2
NCT02297802 No longer available Prior Treatment With PD-0325901 With Ongoing Clinical Response Sharp HealthCare June 2013 --
NCT01347866 Terminated Advanced Cancer Pfizer October 2011 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    Whether the inhibitor PD0325901 interacts with other targets other than MEK?

  • 回答:

    PD0325901 has very high selectivity to MEK. In addition, it can also inhibits VEGF activity according to the reference: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2713590/

MEKシグナル伝達経路

MEK Inhibitors with Unique Features

相関MEK製品

Tags: PD0325901を買う | PD0325901 ic50 | PD0325901供給者 | PD0325901を購入する | PD0325901費用 | PD0325901生産者 | オーダーPD0325901 | PD0325901化学構造 | PD0325901分子量 | PD0325901代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID